2017 年 43 巻 6 号 p. 336-343
Pegfilgrastim (PEG-G) is recommended as a primary prophylactic treatment agent to prevent febrile neutropenia (FN) in regimens with a known 20％ FN occurrence rate. While the prevention of FN by PEG-G is evident in short-term chemotherapy regimens, the effect of PEG-G in long-term daily regimens such as docetaxel, cisplatin, and 5-fluorouracil (DCF) for esophageal cancer is unclear. Therefore, we examined retrospectively the effect of PEG-G (as primary prophylactic treatment) on FN occurrence in patients with DCF therapy. The results were 6 cases (40.0％) of FN occurrence in the PEG-G group and 10 cases (43.5％) in the Non-PEG-G group. Additionally, no significant difference was observed in the occurrence of Grade 4 neutropenia between the PEG-G (7 cases, 46.7％) and Non-PEG-G (15 cases, 65.2％) groups. Based on the above data, primary prophylactic treatment with PEG-G did not prevent FN occurrence in esophageal cancer patients with DCF therapy. It has been reported that the neutrophil nadir of docetaxel is Day 8, suggesting the possibility that the PEG-G administration period needs to be considered.